The University of Chicago Header Logo

Connection

Anthony Reder to Middle Aged

Back to Details
This is a "connection" page, showing publications Anthony Reder has written about Middle Aged.
Anthony Reder
Connection Strength
0.641
Middle Aged
  1. IFN-ß therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses. PLoS One. 2025; 20(9):e0330867.
    View in: PubMed
    Score: 0.058
  2. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
    View in: PubMed
    Score: 0.043
  3. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
    View in: PubMed
    Score: 0.043
  4. Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. Immunotherapy. 2021 01; 13(1):11-17.
    View in: PubMed
    Score: 0.042
  5. Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019 Nov; 49:269-283.
    View in: PubMed
    Score: 0.039
  6. Vitamin D enhances responses to interferon-ß in MS. Neurol Neuroimmunol Neuroinflamm. 2019 11; 6(6):e622.
    View in: PubMed
    Score: 0.039
  7. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment. Patient. 2016 Apr; 9(2):171-80.
    View in: PubMed
    Score: 0.030
  8. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
    View in: PubMed
    Score: 0.025
  9. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol. 2012 Oct; 69(10):1303-9.
    View in: PubMed
    Score: 0.024
  10. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85.
    View in: PubMed
    Score: 0.020
  11. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
    View in: PubMed
    Score: 0.018
  12. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008 Oct 28; 71(18):1390-5.
    View in: PubMed
    Score: 0.018
  13. Impaired inactive limb blood flow regulation in adults with multiple sclerosis during sympathoexcitatory stimuli. Physiol Rep. 2025 12; 13(23):e70694.
    View in: PubMed
    Score: 0.015
  14. Cardiovascular hemodynamic response to peak exercise in individuals with multiple sclerosis. Physiol Rep. 2024 Dec; 12(24):e70150.
    View in: PubMed
    Score: 0.014
  15. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord. 2023 Aug; 76:104794.
    View in: PubMed
    Score: 0.012
  16. Psychometric evaluation of the Chicago Multiscale Depression Inventory in multiple sclerosis patients. Mult Scler. 2003 Mar; 9(2):160-70.
    View in: PubMed
    Score: 0.012
  17. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 Aug; 129(1-2):205-15.
    View in: PubMed
    Score: 0.012
  18. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
    View in: PubMed
    Score: 0.009
  19. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847.
    View in: PubMed
    Score: 0.009
  20. Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study. J Neurol Sci. 2017 Aug 15; 379:151-156.
    View in: PubMed
    Score: 0.008
  21. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult Scler Relat Disord. 2016 Sep; 9:158-62.
    View in: PubMed
    Score: 0.008
  22. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan; 15(1):35-46.
    View in: PubMed
    Score: 0.007
  23. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
    View in: PubMed
    Score: 0.007
  24. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015 Jan; 72(1):31-9.
    View in: PubMed
    Score: 0.007
  25. First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult Scler Relat Disord. 2014 Sep; 3(5):629-38.
    View in: PubMed
    Score: 0.007
  26. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56.
    View in: PubMed
    Score: 0.007
  27. Adrenal size is increased in multiple sclerosis. Arch Neurol. 1994 Feb; 51(2):151-4.
    View in: PubMed
    Score: 0.007
  28. Validity of the Neurology Quality-of-Life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy Behav. 2014 Feb; 31:77-84.
    View in: PubMed
    Score: 0.006
  29. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013 Jul; 120(7):1432-9.
    View in: PubMed
    Score: 0.006
  30. Cystoid macular edema associated with fingolimod use for multiple sclerosis. JAMA Ophthalmol. 2013 Jan; 131(1):103-7.
    View in: PubMed
    Score: 0.006
  31. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992 Dec 15; 114(6):731-6.
    View in: PubMed
    Score: 0.006
  32. Regulation of production of adrenocorticotropin-like proteins in human mononuclear cells. Immunology. 1992 Nov; 77(3):436-42.
    View in: PubMed
    Score: 0.006
  33. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013 Oct; 13(5):443-51.
    View in: PubMed
    Score: 0.006
  34. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012 Jun 05; 78(23):1860-7.
    View in: PubMed
    Score: 0.006
  35. Severe tetanus in immunized patients with high anti-tetanus titers. Neurology. 1992 Apr; 42(4):761-4.
    View in: PubMed
    Score: 0.006
  36. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
    View in: PubMed
    Score: 0.006
  37. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53.
    View in: PubMed
    Score: 0.006
  38. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
    View in: PubMed
    Score: 0.005
  39. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21.
    View in: PubMed
    Score: 0.005
  40. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
    View in: PubMed
    Score: 0.005
  41. Activated suppressor cell function in multiple sclerosis--clinical correlations. J Neuroimmunol. 1988 Mar; 17(4):323-30.
    View in: PubMed
    Score: 0.004
  42. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 Apr; 10(2):126-38.
    View in: PubMed
    Score: 0.003
  43. B-cell differentiation in multiple sclerosis and the effect of intravenous ACTH. Neurology. 1983 Apr; 33(4):442-6.
    View in: PubMed
    Score: 0.003
  44. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997 Jun 01; 99(11):2664-71.
    View in: PubMed
    Score: 0.002
  45. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
    View in: PubMed
    Score: 0.002
  46. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology. 1996 Jul; 47(1):129-39.
    View in: PubMed
    Score: 0.002
  47. Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
    View in: PubMed
    Score: 0.001
  48. Three-dimensional human pattern visual evoked potentials. II. Multiple sclerosis patients. Electroencephalogr Clin Neurophysiol. 1991 Sep-Oct; 80(5):339-46.
    View in: PubMed
    Score: 0.001
  49. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. Ann Neurol. 1991 Jul; 30(1):42-7.
    View in: PubMed
    Score: 0.001
  50. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
    View in: PubMed
    Score: 0.001
  51. Comparison of T8+ cell-mediated suppressor and cytotoxic functions in multiple sclerosis. J Neuroimmunol. 1986 Sep; 12(3):215-24.
    View in: PubMed
    Score: 0.001
  52. Suppressor and cytolytic cell function in multiple sclerosis. Effects of cyclosporine A and interleukin 2. J Clin Invest. 1986 Aug; 78(2):582-6.
    View in: PubMed
    Score: 0.001
  53. Activated suppressor cell dysfunction in progressive multiple sclerosis. J Immunol. 1986 Jul 01; 137(1):137-41.
    View in: PubMed
    Score: 0.001
  54. Senile dementia of Alzheimer's type (SDAT): reduced T8+-cell-mediated suppressor activity. Neurology. 1985 Nov; 35(11):1635-8.
    View in: PubMed
    Score: 0.001
  55. Age-related changes in mechanisms accounting for low levels of polyclonally induced immunoglobulin secretion in humans. Clin Immunol Immunopathol. 1985 May; 35(2):191-9.
    View in: PubMed
    Score: 0.001
  56. Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
    View in: PubMed
    Score: 0.001
  57. T cell regulation of polyclonally induced immunoglobulin secretion in humans. J Immunol. 1984 Apr; 132(4):1779-83.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.